2-(butan-2-ylamino)-4-N-[8-[5-(cyclopropanecarbonyl)pyridin-2-yl]-8-azabicyclo[3.2.1]octan-3-yl]-5-methylbenzene-1,4-dicarboxamide

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 2-(butan-2-ylamino)-4-N-[8-[5-(cyclopropanecarbonyl)pyridin-2-yl]-8-azabicyclo[3.2.1]octan-3-yl]-5-methylbenzene-1,4-dicarboxamide
• 化学式: C₂₉H₃₇N₅O₃
• 分子量: 503.6
• InChiKey: LHGWWAFKVCIILM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA
  申请人：Berg LLC

  公开号：EP2854865B1

  公开（公告）日：2019-02-20
• METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS
  申请人：Race Oncology Ltd.

  公开号：EP3860575A1

  公开（公告）日：2021-08-11
• [EN] METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS<br/>[FR] PROCÉDÉ DE PRÉPARATION ET D'ADMINISTRATION DE FORMULATIONS DE BISANTRÈNE
  申请人：RACE ONCOLOGY LTD

  公开号：WO2020072948A1

  公开（公告）日：2020-04-09

  The present invention is directed to an improved method for preparing bisantrene, specifically bisantrene dihydrochloride, for intravenous administration, as well as to preparations of bisantrene dihydrochloride for intravenous administration. The present invention is also directed to methods for treatment of malignancies treatable by administration of bisantrene, which can include administration of additional anti-neoplastic agents, wherein the bisantrene is prepared by a method according to the present invention.